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Exposure to dioxin-related compounds results in many adverse health effects. Several studies have
examined the effects of dioxin-related compounds on human bone metabolismwith inconsistent results.
In Japan in 1968, accidental human exposure to rice oil contaminated with dioxin-related compounds led
to the development of Yusho oil disease. The aim of this study was to determine whether exposure to
dioxin-related compounds was associated with bone mineral density in Yusho patients. In 2010, 262
women and 227 men underwent dual-energy X-ray absorptiometry bone scans as part of the nationwide
Yusho health examination. Serum levels of polychlorinated dibenzo-p-dioxin, polychlorinated di-
benzofurans, and non-ortho polychlorinated biphenyls were measured using high-resolution gas chro-
matography and high-resolution mass spectrometry. When adjusted for prefecture, 1,2,3,4,7,8-HxCDD
and 2,3,7,8-TCDF were signiﬁcantly positively associated with Z-scores in men. No congeners were
positively associated with Z-scores in women. After adjustment for prefecture and body mass index, one
congener, 1,2,3,4,6,7,8-HpCDD, was negatively associated with Z-scores in women. In contrast, no con-
geners remained signiﬁcant in men after adjusting for body mass index. This may suggest that
1,2,3,4,6,7,8-HpCDD has a negative effect on bone mineral density in women; however, the ﬁndings
should be interpreted carefully, because no increase in the serum level of this congener was observed in
patients with Yusho disease.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Polychlorinated biphenyls (PCBs), polychlorinated dibenzo-p-
dioxin (PCDDs), and polychlorinated di-benzofurans (PCDFs) are a
group of persistent organochlorine compounds that are wide-
spread in the environment. These highly lipophilic compoundsFukushi).
Ltd. This is an open access article uaccumulate in food chains and are detectable in human tissue.
Exposure to these molecules, especially dioxins and dioxin-related
compounds, results in many adverse health effects, including
developmental defects (Walkowiak et al., 2001; Ayotte et al., 2003),
immunotoxicity (Weisglas-Kuperus et al., 2000), reproductive
toxicity (Tsukimori et al., 2008), and endocrine dysfunction (Pluim
et al., 1993).
In Western Japan in 1968, over 1900 people were accidentally
exposed to rice oil contaminated with PCBs and their pyrolytic
byproducts, PCDFs and PCDDs. This food poisoning caused variousnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
J.-i. Fukushi et al. / Chemosphere 145 (2016) 25e3326clinical symptoms, including systemic, dermatological, and
ophthalmological manifestations, and was referred to as Yusho oil
disease (Furue et al., 2005; Yoshimura, 2012). A recent study
showed that the sum of the toxic equivalent concentrations of
PCDDs, PCDFs, and non-ortho PCBs in the blood of Yusho patients in
2006 was 3.3 times higher than that in normal controls. Among
PCDF congeners, which are now considered to be the primary
causative agents of Yusho, 2,3,4,7,8-pentaCDF had the highest
concentration, about 10 times that found in controls (Todaka et al.,
2009). Thus, dioxin-related compounds persisted for a long time in
Yusho patients.
Dioxin-related compounds exert a variety of endocrine effects,
including estrogenic, anti-estrogenic, and anti-androgenic effects
(Ahlborg et al., 1995; Gray, 1998). Given the central role of estrogen
in the development of post-menopausal osteoporosis (Deroo and
Korach, 2006), dioxin-related compounds that can interact with
estrogen receptors or alter estrogen metabolism may affect bone
metabolism. Studies in populations with environmental exposure
to dioxin-related compounds have shown inconsistent results
regarding the effect on bone mineral density (BMD). In 153 Inuit
women with long-term exposure to high levels of organochlorine
compounds due to their traditional seafood diet, univariate ana-
lyses showed that plasma concentrations of PCB153 were inversely
correlated with quantitative ultrasound parameters at the heel
bone. However, this association was not signiﬁcant after adjusting
for confounding variables (Cote et al., 2006). In a population living
close to both the Baltic coast and a river contaminated by PCBs,
PCB118 was inversely associated with BMD in men and positively
associated with BMD in women, suggesting sex-speciﬁc effects of
PCBs on bone metabolism (Hodgson et al., 2008). Very recently,
Eskenazi et al. reported no signiﬁcant negative association between
serum tetrachlorodibenzodioxin (TCDD) concentrations and BMD
in women in Seveso, where people were highly exposed to TCDD
due to an industrial explosion in 1976 (Eskenazi et al., 2014).
It was reported that 3 of 12 infants with congenital Yusho who
were born to mothers with Yusho had natal teeth, spotty calciﬁ-
cation of the skull bones, and open fontanelles at birth, suggesting
impairment of calcium metabolism (Miller, 1985). In a cohort of
Yucheng disease in Taiwan, a similar large-scale food poisoning
occurred in 1979, natal teeth and open fontanelles were also re-
ported in 11 of 127 children (Rogan et al., 1988). In a follow-up
study of Yucheng children, no differences in BMD were observed
when compared with controls (Guo et al., 1994). The aim of the
current study was to examine whether exposure to dioxin-related
compounds was associated with BMD in Yusho patients.
2. Materials and methods
2.1. Subjects
A nationwide Yusho health examination has been conducted
annually in Japan since 1986 tomonitor the health status of chronic
Yusho patients (Furue et al., 2005). Ofﬁcially registered Yusho pa-
tients are those registered by the prefecture ofﬁce and the Ministry
of Health, Labour and Welfare. The examination is open not only to
ofﬁcially registered Yusho patients but also to those who were
exposed to the contaminated rice oil and who regard themselves as
potential victims.
In 2010, 543 individuals participated in the nationwide health
examination, and 14 underwent the same health examination at
Kyushu University hospital. Of these 557 potential subjects, we
included those who were born before the onset of the Yusho ac-
cident. Therefore, 489 subjects were eligible for the analysis. These
included 262 women and 227 menwith mean ages of 66.3 years in
women and 66.9 years in men. The ofﬁcially registered Yushopatients comprised 161 (61.5%) women and 158 (69.6%) men. The
majority of the study subjects lived in Nagasaki (n ¼ 207, 42%) and
Fukuoka (n ¼ 158, 32%), and the rest lived in Kanagawa, Aichi,
Osaka, Tottori, Hiroshima, Yamaguchi, and Kochi. We obtained
written informed consent from all subjects prior to drawing blood
and conducting an interview. The Institutional Ethics Committee
approved the study design (No. 25-166, Kyushu University).
2.2. Clinical and biological parameters
Body height and weight were recorded, and body mass index
(BMI) was calculated as weight (kg) divided by height (m) squared.
Data on osteoporosis were obtained either through face-to-face
interviews by trained nurses (n ¼ 304, 83.3%, Nagasaki and
Fukuoka) or mailed questionnaires (n ¼ 61, 16.7%, other regions).
The questions about osteoporosis addressed history of osteoporosis
and history of medications for osteoporosis.
BMD was measured at the distal radius of non-dominant arms
using a dual-energy X-ray absorptiometry (DXA) method. Partici-
pants were 66 men and 100 women in Fukuoka, 90 men and 112
women in Nagasaki, and 41 men and 39 women in other regions.
Four different devices were used: DCS-600EX (Aloka, Tokyo, Japan,
n ¼ 173, Fukuoka, Osaka, and Kochi), DTX-200 (Osteometer Medi-
tech Inc. CA, n ¼ 191, Nagasaki), Discovery Wi (Hologic, Inc. MA,
n ¼ 20, Hiroshima, Tottori), and Delphi (Hologic, Inc., n ¼ 12,
Kanagawa). These devices are used worldwide, and quality assur-
ance procedures have been performed (Hangartner, 2007; Hans
et al., 2008). Z-scores, which are the number of standard de-
viations away from the average of the age-matched reference BMD
values, were used for analysis.
The clinical characteristics of the study subjects are shown in
Table 1.
2.3. Measurements of PCBs and dioxin-related compounds
The serum levels of dioxin-related compounds were measured
during the nationwide Yusho health examination (Todaka et al.,
2009). Brieﬂy, 10-ml blood samples were collected, and the levels
of PCDDs, PCDFs, and non-ortho PCBs in the blood were measured
using high-resolution gas chromatography and high-resolution
mass spectrometry at the Fukuoka Institute of Health and Envi-
ronmental Sciences (Todaka et al., 2003). Twenty-nine different
congeners were measured: 7 PCDDs, 10 PCDFs, and 12 PCBs. Of the
12 PCBs, 4 congeners detected in more than half of the participants
were further analyzed.
2.4. Data analysis and statistical methods
Because the incidence of osteoporosis differs signiﬁcantly be-
tween women and men, we separately assessed the relationships
between the concentrations of dioxin-related compounds and BMD
measures for each gender expressed by Z-score. The associations
between Z-score, BMI, and levels of dioxin-related compounds
were analyzed using linear regression models. In cases in which
concentrations of dioxin-related compounds were lower than the
detection limit, a value of half the detection limit was used.
Considering their highly skewed distributions, the concentrations
of dioxin-related compounds were log10-transformed and included
in the model. The regions of residency were included in the model
as dummy variables for Fukuoka, Nagasaki, and other prefectures. A
two-sided P < 0.05 was considered statistically signiﬁcant in the
statistical tests. All statistical analyses were performed using Stata
version 13 statistical analysis software (Stata, College Station, TX,
USA).
Table 1
Demographic characteristics of subjects [n (%)]. Registration refers to the status of ofﬁcial registration as a Yusho patient by the prefecture ofﬁce and the Ministry of Health,
Labour and Welfare.
Characteristics Woman with osteoporosis medication Woman without osteoporosis medication All women Men
Total 40 (15.3) 222 (84.7) 262 (100.0) 227 (100.0)
Registration
registered 26 (65.0) 135 (60.8) 161 (61.5) 158 (69.6)
non-registered 14 (35.0) 87 (39.2) 101 (38.5) 69 (30.4)
Age (years)
49 1 (2.5) 22 (9.9) 23 (8.8) 20 (8.8)
50e59 1 (2.5) 61 (27.5) 62 (23.7) 45 (19.8)
60e69 8 (20.0) 53 (23.9) 61 (23.3) 57 (25.1)
70e79 21 (52.5) 59 (26.6) 80 (30.5) 71 (31.3)
80þ 9 (22.5) 27 (12.2) 36 (13.7) 34 (15.0)
Prefecture
Kanagawa 1 (2.5) 7 (3.2) 8 (3.1) 4 (1.8)
Aichi 0 (0.0) 8 (3.6) 8 (3.1) 5 (2.2)
Osaka 1 (2.5) 13 (5.9) 14 (5.3) 7 (3.1)
Tottori 0 (0.0) 1 (0.5) 1 (0.4) 1 (0.4)
Hiroshima 0 (0.0) 15 (6.8) 15 (5.7) 52 (22.9)
Yamaguchi 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Kochi 1 (2.5) 4 (1.8) 5 (1.9) 6 (2.6)
Fukuoka 11 (27.5) 83 (37.4) 94 (35.9) 62 (27.3)
Nagasaki 26 (65.0) 91 (41.0) 117 (44.7) 90 (39.6)
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The subjects' demographic characteristics are shown in Tables 1
and 2. About two-thirds of the subjects were ofﬁcially registered
Yusho patients, and more than 90% (91%) were over age 50. The
majority of the subjects lived in Nagasaki or Fukuoka prefectures,
where the highest number of Yusho poisonings occurred (Furue
et al., 2005). The average ages of subjects were 66.3 years in
women and 66.9 in men. The average BMIs were 23.1 (kg/m2) in
women and 23.8 in men. About one quarter (68 women, 26%; 62
men, 27%) of the subjects were obese (BMI > 25). The average Z-
scores of BMD (SD) were 0.53 in women and 0.68 in men. The
distributions of Z-scores and age are shown in Fig. 1. About one
third (35%) of women (n ¼ 80) had low BMD, deﬁned as a T-score
less than 70, while only 4% of men (n ¼ 7) had low BMD. Forty
women reported a history of medication for osteoporosis (Table 2).
The distributions of serum dioxin-related compounds in various
subpopulations are shown in Table 2. As previously reported, blood
concentrations of 2,3,4,7,8-PeCDF, 1,2,3,4,7, 8-HxCDF, and
1,2,3,6,7,8-HxCDF were higher in the subjects who participated in
the nationwide Yusho health examination than in controls (Todaka
et al., 2007). The blood concentrations of 2,3,4,7,8-PeCDF,
1,2,3,4,7,8-HxCDF, and 1,2,3,6,7,8-HxCDF in the Yusho patients were
89.9, 19.8, and 10.1 pg/g lipid, respectively, 5.3, 4.0, and 1.8 times
higher, respectively, than those in controls (Todaka et al., 2007).
As reported in other cohorts (Greendale and Judd, 1993; Collins
et al., 2007), Z-scores of BMD were positively associated with BMI
in both women and men (Table 3 and Fig. 2).
The association between 10-fold increases in serum dioxin-
related compound levels and Z-scores of BMD is shown in
Table 4. When adjusted for prefecture, 1,2,3,4,7,8-HxCDD and
2,3,7,8-TCDF were signiﬁcantly positively associated with Z-scores
inmen. In contrast, no congeners were positively associatedwith Z-
scores in women, regardless of the history of treatment for osteo-
porosis (Table 4).
The association between serum dioxin-related compounds
levels and BMI is shown in Table 5.1,2,3,7,8,9-HxCDDwas positively
associatedwith BMI in bothmen andwomen. A positive association
of BMI was observed with 1,2,3,4,6,7,8-HpCDD, OCDD, and
3,30,4,40,5-PeCB(#126) in women and with 1,2,3,4,7,8-HxCDD,
1,2,3,6,7,8-HxCDD, and 1,2,3,6,7,8-HxCDF in men. In contrast,
3,30,4,40,5,50-HxCB(#169) was negatively associated with BMI inboth women and men.
The association between Z-score of BMD and dioxins after
adjusting for BMI and prefecture is shown in Table 6. Only one
congener, 1,2,3,4,6,7,8-HpCDD, was negatively associated with Z-
scores inwomen regardless of the history of osteoporosis treatment
(Fig. 3). In contrast, no congeners remained signiﬁcant in men after
adjustment for BMI.
4. Discussion
This is the largest study to date examining the association be-
tween serum dioxin-related compounds and BMD. Among 29
congeners examined in this survey, 2 were positively associated
with BMD inmenwhen adjusted for prefecture, but this association
was not signiﬁcant after adjusting for BMI. In women, by contrast,
only one congener, 1,2,3,4,6,7,8-HpCDD, was negatively associated
with Z-score of BMD after adjusting for BMI and prefecture. How-
ever, the results in women should be interpreted carefully, because
no increases in the serum levels of 1,2,3,4,6,7,8-HpCDD were
observed in Yusho patients (mean 63 pg/g lipid) when compared
with controls (mean 80 pg/g lipid) (Todaka et al., 2007). Since our
study found that BMI was associated with both BMD and
1,2,3,4,6,7,8-HpCDD in women, residual confounding might still be
present. Considering that little information is available about the
biological function of 1,2,3,4,6,7,8-HpCDD, whose toxicity equiva-
lency factor value is as low as 0.01, further conﬁrmation through
future studies is required.
Several studies have examined the effects of dioxin-related
compounds on human bone metabolism with inconsistent re-
sults. Serum PCB-167 concentrations were positively associated
with BMD in a Swedish general cohort of 115 men (Glynn et al.,
2000). In a cohort of Swedish ﬁsherman and their wives (196
men and 184 women), serum PCB-153 concentrations were nega-
tively associatedwith BMD based on the univariate analysis, but the
association was not signiﬁcant after adjusting for age and BMI
(Wallin et al., 2005). In a study of a general Swedish population
living near the Baltic sea (154 men and 167 women), serum dioxin-
like PCB-118 concentrations were associated with BMD negatively
in men but positively in women (Hodgson et al., 2008).
Experimental exposure to dioxin-related compounds revealed
inconsistent results regarding bone metabolism in animal models.
In mice, infantile exposure to TCDD impaired bone mineralization
Table 2
Demographic characteristics of subjects. Detection limits of the congeners are as follows: # 1 pg/g lipid, ## 2 pg/g lipid, * 4 pg/g lipid, ** 10 pg/g lipid.
Woman with osteoporosis medication Woman without osteoporosis medicaiton All women Men
n Median min Max Mean SD n Median min Max Mean SD n Median min Max Mean SD n Median min Max Mean SD
Age (years) 40 73.5 49 85 73.1 7.5 222 64.0 42 96 65.1 11.9 262 66.0 42 96 66.3 11.7 227 68.0 42 93 66.9 11.8
BMI (kg/m2)BMI (kg/m2) 40 23.5 16.7 30.1 23.0 3.3 214 22.7 15.5 34.7 23.1 3.7 254 22.8 15.5 34.7 23.1 3.7 221 23.7 13.8 34.4 23.8 3.1
BMD (g/cm2)BMD (g/cm2) 38 0.34 0.19 0.50 0.35 0.08 186 0.45 0.21 0.93 0.47 0.14 224 0.44 0.19 0.93 0.45 0.14 172 0.64 0.34 1.09 0.64 0.13
Z_score (SD) 38 0.01 2.56 6.10 0.19 1.54 186 0.60 3.18 7.00 0.60 1.58 224 0.51 3.18 7.00 0.53 1.57 172 0.70 3.80 7.40 0.68 1.77
T score (%) 38 65.0 39.0 99.0 65.7 12.9 186 80.0 44.0 128.0 81.2 18.5 224 77.0 39.0 128.0 78.5 18.6 172 95.5 58.0 139.0 94.2 13.3
Lipid (%) 34 0.31 0.24 0.48 0.33 0.07 179 0.31 0.21 0.49 0.33 0.06 213 0.31 0.21 0.49 0.33 0.06 170 0.30 0.20 0.49 0.30 0.05
Congeners (pg/g lipid)
2,3,7,8-TCDD#2,3,7,8-TCDD# 34 1.79 0.25 4.01 1.95 0.78 179 1.66 0.25 6.30 1.67 1.00 213 1.71 0.25 6.30 1.71 0.97 170 1.62 0.25 4.22 1.60 1.00
1,2,3,7,8-PeCDD#
1,2,3,7,8-PeCDD#
34 10.39 4.69 31.92 10.97 5.06 179 8.38 1.61 47.61 9.87 6.24 213 8.76 1.61 47.61 10.05 6.07 170 7.47 1.49 23.85 8.29 4.31
1,2,3,4,7,8-HxCDD##
1,2,3,4,7,8-HxCDD##
34 2.71 0.50 6.57 3.08 1.68 179 2.76 0.50 10.00 2.88 1.96 213 2.76 0.50 10.00 2.91 1.92 170 2.43 0.50 14.05 2.36 1.92
1,2,3,6,7,8-HxCDD##
1,2,3,6,7,8-HxCDD##
34 26.93 10.82 176.21 41.11 37.17 179 29.69 7.02 266.59 41.76 38.62 213 29.28 7.02 266.59 41.66 38.31 170 22.23 2.46 173.20 30.19 27.42
1,2,3,7,8,9-HxCDD##
1,2,3,7,8,9-HxCDD##
34 4.05 0.50 25.84 4.95 4.90 179 3.50 0.50 18.95 4.35 3.34 213 3.51 0.50 25.84 4.45 3.63 170 2.87 0.50 23.80 3.15 2.74
1,2,3,4,6,7,8-HpCDD##
1,2,3,4,6,7,8-HpCDD##
34 37.76 12.45 171.13 47.70 35.09 179 34.03 13.29 624.05 44.12 53.58 213 34.63 12.45 624.05 44.69 51.02 170 27.75 9.01 268.54 34.92 25.63
OCDD*OCDD* 34 660.24 232.47 4078.94 846.89 716.60 179 598.79 197.90 4926.46 716.24 532.67 213 600.45 197.90 4926.46 737.09 566.10 170 516.73 151.75 2881.27 639.50 402.00
2,3,7,8-TCDF# 34 1.37 0.25 4.91 1.68 1.38 179 1.11 0.25 9.48 1.56 1.74 213 1.16 0.25 9.48 1.58 1.69 170 1.27 0.25 12.64 1.70 2.08
1,2,3,7,8-PeCDF# 34 1.19 0.25 2.77 1.16 0.83 179 0.25 0.25 6.44 0.81 0.97 213 0.25 0.25 6.44 0.87 0.96 170 0.25 0.25 10.86 1.01 1.23
2,3,4,7,8-PeCDF# 34 51.73 9.29 969.49 142.61 220.15 179 33.29 4.56 1494.28 126.97 216.55 213 35.63 4.56 1494.28 129.47 216.68 170 23.27 2.80 673.25 57.77 91.30
1,2,3,4,7,8-HxCDF## 34 9.08 0.50 324.52 33.25 63.90 179 7.05 0.50 487.60 27.22 55.15 213 7.49 0.50 487.60 28.19 56.52 170 4.24 0.50 186.79 10.69 22.60
1,2,3,6,7,8-HxCDF## 34 9.02 2.72 136.10 16.14 24.50 179 6.25 0.50 198.56 12.48 19.36 213 6.45 0.50 198.56 13.06 20.25 170 5.02 0.50 77.30 7.33 9.03
2,3,4,6,7,8-HxCDF## 34 0.50 0.50 4.15 1.00 1.05 179 0.50 0.50 9.62 0.77 0.99 213 0.50 0.50 9.62 0.81 1.00 170 0.50 0.50 7.03 0.89 1.03
1,2,3,7,8,9-HxCDF## 34 0.50 0.50 0.50 0.50 0.00 179 0.50 0.50 0.50 0.50 0.00 213 0.50 0.50 0.50 0.50 0.00 170 0.50 0.50 0.50 0.50 0.00
1,2,3,4,6,7,8-HpCDF## 34 1.25 0.50 12.59 2.44 3.07 179 0.50 0.50 39.13 2.11 3.88 213 0.50 0.50 39.13 2.16 3.76 170 0.50 0.50 24.61 1.87 2.72
1,2,3,4,7,8,9-HpCDF## 34 0.50 0.50 0.50 0.50 0.00 179 0.50 0.50 3.32 0.52 0.21 213 0.50 0.50 3.32 0.51 0.19 170 0.50 0.50 0.50 0.50 0.00
OCDF* 34 1.00 1.00 1.00 1.00 0.00 179 1.00 1.00 5.11 1.02 0.31 213 1.00 1.00 5.11 1.02 0.28 170 1.00 1.00 1.00 1.00 0.00
3,4,40 ,5-TCB(#81)** 34 2.50 2.50 16.67 3.64 3.30 179 2.50 2.50 15.09 2.83 1.80 213 2.50 2.50 16.67 2.96 2.12 170 2.50 2.50 30.80 3.70 4.14
3,30,4,40-TCB(#77)** 34 2.50 2.50 31.85 7.06 7.15 179 2.50 2.50 25.27 4.71 4.84 213 2.50 2.50 31.85 5.09 5.33 170 2.50 2.50 38.29 6.39 6.39
3,30,4,40 ,5-PeCB(#126)** 34 123.59 34.17 520.99 145.92 109.52 179 82.59 2.50 491.57 101.95 74.20 213 85.95 2.50 520.99 108.96 82.16 170 98.91 2.50 684.12 124.33 110.48
3,30,4,40 ,5,50-HxCB(#169)** 34 140.2 31.63 585.37 188.38 128.62 179 84.91 5.00 1281.08 135.02 143.77 213 97.57 5.00 1281.08 142.77 142.67 170 125.49 5.00 838.81 152.73 122.25
Detection limits of the congeners are as follows; # 1 pg/g lipid, ## 2 pg/g lipid, * 4 pg/g lipid, ** 10 pg/g lipid.
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Fig. 1. The distributions of Z-scores of BMD and age. No signiﬁcant differences were observed between ofﬁcially registered and non-registered subjects.
Table 3
The associations between Z-score of BMD and BMI analyzed by linear regression models adjusted for region of residency.
Regression coefﬁcient (b)
b SE of b Lower 95% Upper 95% P
Women without osteoporosis medication 0.13903 0.02943 0.08095 0.19710 <0.0001
All women 0.15112 0.02678 0.09834 0.20390 <0.0001
Men 0.13210 0.04088 0.05139 0.21280 0.001
J.-i. Fukushi et al. / Chemosphere 145 (2016) 25e33 29resulting from reduction of osteoblastic activity (Nishimura et al.,
2009). In rats, treatment with PCB-126 decreased both minerali-
zation in vertebral bone and serum levels of vitamin D (Alvarez-
Lloret et al., 2009). Also in rats, PCB-126-exposure resulted in
shorter length and decreased torsional stiffness in long bones (Lind
et al., 2000). In contrast, perinatal exposure to PCB-153, but not
PCB-126, increased trabecular BMD of the metaphysis in female
goat offspring (Lundberg et al., 2006). In sheep, in utero exposure to
PCB-153 increased cortical BMD in female fetuses but not in male
fetuses or adult females (Gutleb et al., 2010). Finally, in monkeys, in
utero and lactational exposure toTCDD increased trabecular BMC in
females and energy absorption in the three-point bending test in
males (Hermsen et al., 2008). These studies, along with our ob-
servations, indicate that the effects of dioxin-related compounds on
bone metabolism depend on the species, sex, and timing of
exposure.Fig. 2. The associations between Z-score of BMD and BMI. Z-scores of BBonemetabolism is regulated by the balance between formation
by osteoblasts and resorption by osteoclast. In vitro studies have
revealed that very low doses of TCDD inhibit the differentiation of
both osteoblasts and osteoclasts from bone marrow stem cells
(Korkalainen et al., 2009). These inhibitory effects were not
observed in mice genetically deﬁcient for the aryl hydrocarbon
receptor (AhR), suggesting that AhR mediates the effect of TCDD on
bone cells. Therefore, the net volume of bone may depend on the
sensitivity of AhR to dioxins in osteoblasts and osteoclasts, which
could differ among species or ethnicities. Moreover, the functions
of these cells are strongly affected by estrogen receptor signaling,
which can cross-talk with AhR (Sohoni and Sumpter,1998). Because
dioxin-related compounds modulate this cross-talk and act as
endocrine disruptors (Birnbaum and Cummings, 2002), it is difﬁ-
cult to predict the effects of these compounds on bone metabolism
in vivo.MD were positively associated with BMI in both women and men.
Table 4
The associations between Z-score of BMD and serum levels of dioxin-related compounds analyzed by linear regression models adjusted for region of residency.
log10 congeners (pg/g lipid) Regression coefﬁcient (b)
Women without osteoporosis medication b SE of b lower 95% upper 95% P
2,3,7,8-TCDD 0.34417 0.35472 0.35713 1.04548 0.33
1,2,3,7,8-PeCDD 0.09579 0.56910 1.02935 1.22093 0.87
1,2,3,4,7,8-HxCDD 0.48147 0.32870 1.13134 0.16839 0.15
1,2,3,6,7,8-HxCDD 0.45984 0.46001 1.36930 0.44961 0.32
1,2,3,7,8,9-HxCDD 0.21667 0.35556 0.91963 0.48629 0.54
1,2,3,4,6,7,8-HpCDD 0.56524 0.49830 1.55041 0.41992 0.26
OCDD 0.21955 0.55658 1.31994 0.88085 0.69
2,3,7,8-TCDF 0.22446 0.25868 0.28696 0.73587 0.39
2,3,4,7,8-PeCDF 0.15071 0.22370 0.29155 0.59297 0.50
1,2,3,4,7,8-HxCDF 0.23382 0.20654 0.17451 0.64216 0.26
1,2,3,6,7,8-HxCDF 0.16069 0.31626 0.46458 0.78596 0.61
3,30 ,4,40 ,5-PeCB(#126) 0.73039 0.43106 0.12183 1.58261 0.09
3,30 ,4,40 ,5,50-HxCB(#169) 0.28686 0.38184 0.46805 1.04177 0.45
All women b SE of b lower 95% upper 95% P
2,3,7,8-TCDD 0.34430 0.34009 0.32688 1.01548 0.31
1,2,3,7,8-PeCDD 0.13767 0.52791 0.90418 1.17952 0.79
1,2,3,4,7,8-HxCDD 0.43498 0.30605 1.03898 0.16901 0.16
1,2,3,6,7,8-HxCDD 0.32974 0.41446 1.14770 0.48822 0.43
1,2,3,7,8,9-HxCDD 0.05881 0.31395 0.67839 0.56078 0.85
1,2,3,4,6,7,8-HpCDD 0.49305 0.45368 1.38839 0.40230 0.28
OCDD 0.15934 0.49150 1.12934 0.81067 0.75
2,3,7,8-TCDF 0.35006 0.23645 0.11659 0.81671 0.14
2,3,4,7,8-PeCDF 0.14811 0.20413 0.25475 0.55098 0.47
1,2,3,4,7,8-HxCDF 0.26971 0.18639 0.09814 0.63756 0.15
1,2,3,6,7,8-HxCDF 0.23428 0.28601 0.33016 0.79873 0.41
3,30 ,4,40 ,5-PeCB(#126) 0.67472 0.39753 0.10983 1.45926 0.09
3,30 ,4,40 ,5,50-HxCB(#169) 0.18449 0.34903 0.50433 0.87331 0.60
Men b SE of b lower 95% upper 95% P
2,3,7,8-TCDD 0.59200 0.36671 0.13387 1.31787 0.11
1,2,3,7,8-PeCDD 0.67924 0.61435 0.53682 1.89530 0.27
1,2,3,4,7,8-HxCDD 0.70953 0.35436 0.00809 1.41097 0.047
1,2,3,6,7,8-HxCDD 0.13281 0.53358 0.92338 1.18900 0.8
1,2,3,7,8,9-HxCDD 0.62583 0.37106 0.10867 1.36033 0.09
1,2,3,4,6,7,8-HpCDD 0.99323 0.62102 0.23603 2.22250 0.11
OCDD 0.84614 0.60392 0.34929 2.04157 0.16
2,3,7,8-TCDF 0.61976 0.28668 0.05230 1.18722 0.033
2,3,4,7,8-PeCDF 0.08957 0.30865 0.52138 0.70052 0.77
1,2,3,4,7,8-HxCDF 0.16523 0.26184 0.35306 0.68353 0.53
1,2,3,6,7,8-HxCDF 0.31286 0.33424 0.34875 0.97447 0.35
3,30 ,4,40 ,5-PeCB(#126) 0.70686 0.39264 0.07035 1.48407 0.07
3,30 ,4,40 ,5,50-HxCB(#169) 0.18626 0.45965 0.72359 1.09612 0.69
Table 5
The associations between BMI and serum levels of dioxin-related compounds analyzed by linear regression models adjusted for region of residency.
log10 congeners (pg/g lipid) Regresion coefﬁcient (b)
Women without osteoporosis medication b SE of b lower 95% upper 95% P
2,3,7,8-TCDD 0.00677 0.00837 0.00978 0.02332 0.42
1,2,3,7,8-PeCDD 0.00218 0.00525 0.00820 0.01255 0.68
1,2,3,4,7,8-HxCDD 0.00870 0.00909 0.00928 0.02667 0.34
1,2,3,6,7,8-HxCDD 0.00466 0.00655 0.00828 0.01759 0.48
1,2,3,7,8,9-HxCDD 0.02169 0.00822 0.00544 0.03794 0.009
1,2,3,4,6,7,8-HpCDD 0.01791 0.00579 0.00646 0.02936 0.002
OCDD 0.01561 0.00525 0.00524 0.02599 0.003
2,3,7,8-TCDF 0.01398 0.01163 0.00901 0.03697 0.23
2,3,4,7,8-PeCDF 0.01047 0.01352 0.01626 0.03719 0.44
1,2,3,4,7,8-HxCDF 0.02642 0.01450 0.00224 0.05507 0.07
1,2,3,6,7,8-HxCDF 0.01351 0.00956 0.00538 0.03240 0.16
3,30 ,4,40 ,5-PeCB(#126) 0.01673 0.00674 0.00342 0.03004 0.014
3,30 ,4,40 ,5,50-HxCB(#169) 0.00925 0.00780 0.02467 0.00617 0.24
All women b SE of b lower 95% upper 95% P
2,3,7,8-TCDD 0.00509 0.00683 0.00838 0.01856 0.46
1,2,3,7,8-PeCDD 0.00026 0.00446 0.00854 0.00905 0.95
1,2,3,4,7,8-HxCDD 0.00560 0.00766 0.00951 0.02071 0.47
1,2,3,6,7,8-HxCDD 0.00261 0.00566 0.00855 0.01376 0.65
1,2,3,7,8,9-HxCDD 0.02506 0.00740 0.01046 0.03965 <0.001
1,2,3,4,6,7,8-HpCDD 0.01616 0.00491 0.00649 0.02584 0.001
OCDD 0.01615 0.00463 0.00702 0.02528 <0.001
2,3,7,8-TCDF 0.00787 0.00990 0.01165 0.02738 0.43
2,3,4,7,8-PeCDF 0.00105 0.01153 0.02378 0.02168 0.93
1,2,3,4,7,8-HxCDF 0.01634 0.01241 0.00813 0.04080 0.19
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Table 5 (continued )
log10 congeners (pg/g lipid) Regresion coefﬁcient (b)
1,2,3,6,7,8-HxCDF 0.00980 0.00806 0.00609 0.02569 0.23
3,30 ,4,40 ,5-PeCB(#126) 0.01390 0.00590 0.00227 0.02553 0.019
3,30 ,4,40 ,5,50-HxCB(#169) 0.01425 0.00661 0.02728 0.00122 0.032
Men b SE of b lower 95% upper 95% P
2,3,7,8-TCDD 0.01501 0.00941 0.00357 0.03360 0.11
1,2,3,7,8-PeCDD 0.00539 0.00564 0.00574 0.01653 0.34
1,2,3,4,7,8-HxCDD 0.03112 0.00987 0.01163 0.05062 0.002
1,2,3,6,7,8-HxCDD 0.01493 0.00674 0.00161 0.02824 0.028
1,2,3,7,8,9-HxCDD 0.02577 0.00985 0.00631 0.04522 0.010
1,2,3,4,6,7,8-HpCDD 0.00570 0.00588 0.00592 0.01732 0.33
OCDD 0.00667 0.00592 0.00501 0.01836 0.26
2,3,7,8-TCDF 0.01932 0.01244 0.00525 0.04390 0.12
2,3,4,7,8-PeCDF 0.00577 0.01189 0.01771 0.02925 0.63
1,2,3,4,7,8-HxCDF 0.02585 0.01352 0.00085 0.05255 0.06
1,2,3,6,7,8-HxCDF 0.02198 0.01005 0.00214 0.04182 0.030
3,30 ,4,40 ,5-PeCB(#126) 0.00823 0.00876 0.00906 0.02552 0.35
3,30 ,4,40 ,5,50-HxCB(#169) 0.01590 0.00750 0.03071 0.00110 0.035
J.-i. Fukushi et al. / Chemosphere 145 (2016) 25e33 31Previous studies have reported a positive association between
BMI and concentrations of serum dioxin-related compounds (Wolff
et al., 2005; Kim et al., 2011). Our results conﬁrmed these reports as
several congeners were positively associated with BMI. However,
we also observed that 3,30,4,40,5,50-HxCB (#169) was negatively
associated with BMI in both men and women. The interpretation ofTable 6
The associations between Z-score of BMD and serum levels of dioxin-related compound
log10 congeners (pg/g lipid)
Women without osteoporosis medication b SE
2,3,7,8-TCDD 0.24653 0.3
1,2,3,7,8-PeCDD 0.02223 0.5
1,2,3,4,7,8-HxCDD 0.58707 0.3
1,2,3,6,7,8-HxCDD 0.56041 0.4
1,2,3,7,8,9-HxCDD 0.54909 0.3
1,2,3,4,6,7,8-HpCDD 1.12887 0.4
OCDD 0.79860 0.5
2,3,7,8-TCDF 0.11592 0.2
2,3,4,7,8-PeCDF 0.09430 0.2
1,2,3,4,7,8-HxCDF 0.11143 0.1
1,2,3,6,7,8-HxCDF 0.01455 0.3
3,30 ,4,40 ,5-PeCB(#126) 0.38683 0.4
3,30 ,4,40 ,5,50-HxCB(#169) 0.45001 0.3
All women b SE
2,3,7,8-TCDD 0.22263 0.3
1,2,3,7,8-PeCDD 0.07541 0.4
1,2,3,4,7,8-HxCDD 0.53532 0.2
1,2,3,6,7,8-HxCDD 0.37711 0.3
1,2,3,7,8,9-HxCDD 0.40665 0.2
1,2,3,4,6,7,8-HpCDD 1.12340 0.4
OCDD 0.84142 0.4
2,3,7,8-TCDF 0.25757 0.2
2,3,4,7,8-PeCDF 0.14123 0.1
1,2,3,4,7,8-HxCDF 0.17752 0.1
1,2,3,6,7,8-HxCDF 0.10889 0.2
3,30 ,4,40 ,5-PeCB(#126) 0.28089 0.3
3,30 ,4,40 ,5,50-HxCB(#169) 0.42723 0.3
Men b SE
2,3,7,8-TCDD 0.47093 0.3
1,2,3,7,8-PeCDD 0.53667 0.6
1,2,3,4,7,8-HxCDD 0.52476 0.3
1,2,3,6,7,8-HxCDD 0.15720 0.5
1,2,3,7,8,9-HxCDD 0.43843 0.3
1,2,3,4,6,7,8-HpCDD 0.85215 0.6
OCDD 0.72309 0.5
2,3,7,8-TCDF 0.52171 0.2
2,3,4,7,8-PeCDF 0.04679 0.3
1,2,3,4,7,8-HxCDF 0.04660 0.2
1,2,3,6,7,8-HxCDF 0.14234 0.3
3,30 ,4,40 ,5-PeCB(#126) 0.66539 0.3
3,30 ,4,40 ,5,50-HxCB(#169) 0.36678 0.4this discrepancy among the congeners is unclear at this stage and
should be elucidated through future projects.
A limitation of this study is the lack of information about par-
ticipants' menopausal states, because BMD decreases drastically
after menopause (Sowers et al., 1992), and the majority (82%) of
female subjects may have been post-menopausal (over 55 yearss analyzed using linear regression models adjusted for BMI and region of residency.
Regresion coefﬁcient (b)
of b lower 95% upper 95% P
3616 0.41813 0.91119 0.46
3760 1.04069 1.08516 0.97
0964 1.19927 0.02514 0.06
3385 1.41822 0.29739 0.20
4099 1.22329 0.12510 0.11
7813 2.07421 0.18353 0.020
3714 1.86062 0.26341 0.14
4604 0.37054 0.60239 0.64
1180 0.32446 0.51306 0.66
9789 0.27983 0.50269 0.57
0085 0.58028 0.60938 0.96
1882 0.44124 1.21491 0.36
6113 0.26401 1.16403 0.21
of b lower 95% upper 95% P
1900 0.40694 0.85221 0.49
9326 0.89809 1.04890 0.88
8524 1.09828 0.02763 0.06
8684 1.14059 0.38637 0.33
9880 0.99637 0.18306 0.18
3123 1.97447 0.27232 0.010
7162 1.77221 0.08937 0.08
2211 0.18079 0.69592 0.25
9064 0.23502 0.51749 0.46
7555 0.16896 0.52399 0.31
6862 0.42126 0.63905 0.69
8223 0.47348 1.03526 0.46
2784 0.21980 1.07427 0.19
of b lower 95% upper 95% P
6096 0.24363 1.18548 0.19
0099 0.65304 1.72639 0.37
5524 0.17847 1.22799 0.14
2915 1.20471 0.89031 0.77
7051 0.29503 1.17188 0.24
0784 0.35113 2.05542 0.16
9036 0.44559 1.89177 0.22
8285 0.03821 1.08163 0.07
0075 0.54859 0.64216 0.88
5876 0.46563 0.55883 0.86
3223 0.51534 0.80002 0.67
8260 0.09200 1.42278 0.08
5059 0.52521 1.25877 0.42
Fig. 3. The association between 1,2,3,4,6,7,8-HpCDD and dioxins after adjusting for BMI and prefecture. 1,2,3,4,6,7,8-HpCDD was negatively associated with Z-scores in women
regardless of the history of osteoporosis treatment. No signiﬁcant association was observed in men.
J.-i. Fukushi et al. / Chemosphere 145 (2016) 25e3332old). In addition, the lack of information about smoking, alcohol
intake, and past history may have resulted in a weakened estima-
tion of the association between serum dioxin-related compounds
and BMD. Despite these weaknesses, our study is one of the largest
to have examined the effects of dioxin-related compounds on BMD.
Unlike previous studies, we measured the serum levels of as many
as 29 dioxin-related compounds using a reliable method.
5. Conclusions
We observed a negative association between BMD and the
serum concentrations of one dioxin-related compound,
1,2,3,4,6,7,8-HpCDD, in women from the nationwide Yusho health
examination. Serum concentrations of dioxin-related compounds
were not associated with BMD in men. However, care should be
taken in interpreting this observation, because no increase in the
serum levels of 1,2,3,4,6,7,8-HpCDD was observed in Yusho pa-
tients, and residual confounding may be present. We plan to follow
this group in future studies, collecting information about meno-
pausal state, life history, and history of fractures.
Acknowledgments
This study was supported by a Health and Labour Sciences
Research Grant from the Ministry of Health, Labour and Welfare,
Japan; Research on Food Safety (project nos:H22-Designated
Research-001 and H24-Designated Research-014), and JSPS
KAKENHI Grant Number 26462301. We are grateful to Dr. Yoshiko
Takao and Dr. Junboku Kajiwara for the measurement of dioxin-
related compounds.
The authors declare that they have no competing ﬁnancial
interests.
References
Ahlborg, U.G., Lipworth, L., Titus-Ernstoff, L., Hsieh, C.C., Hanberg, A., Baron, J.,
Trichopoulos, D., Adami, H.O., 1995. Organochlorine compounds in relation to
breast cancer, endometrial cancer, and endometriosis: an assessment of the
biological and epidemiological evidence. Crit. Rev. Toxicol. 25, 463e531.
Alvarez-Lloret, P., Lind, P.M., Nyberg, I., Orberg, J., Rodriguez-Navarro, A.B., 2009.
Effects of 3,3',4,4',5-pentachlorobiphenyl (PCB126) on vertebral bone mineral-
ization and on thyroxin and vitamin D levels in Sprague-Dawley rats. Toxicol.
Lett. 187, 63e68.
Ayotte, P., Muckle, G., Jacobson, J.L., Jacobson, S.W., Dewailly, E., Inuit Cohort, S.,2003. Assessment of pre- and postnatal exposure to polychlorinated biphenyls:
lessons from the Inuit Cohort Study. Environ. Health Perspect. 111, 1253e1258.
Birnbaum, L.S., Cummings, A.M., 2002. Dioxins and endometriosis: a plausible hy-
pothesis. Environ. Health Perspect. 110, 15e21.
Collins, J.J., Bodner, K., Burns, C.J., Budinsky, R.A., Lamparski, L.L., Wilken, M.,
Martin, G.D., Carson, M.L., 2007. Body mass index and serum chlorinated
dibenzo-p-dioxin and dibenzofuran levels. Chemosphere 66, 1079e1085.
Cote, S., Ayotte, P., Dodin, S., Blanchet, C., Mulvad, G., Petersen, H.S., Gingras, S.,
Dewailly, E., 2006. Plasma organochlorine concentrations and bone ultrasound
measurements: a cross-sectional study in peri-and postmenopausal Inuit
women from Greenland. Environ. Health 5, 33.
Deroo, B.J., Korach, K.S., 2006. Estrogen receptors and human disease. J. Clin. Invest.
116, 561e570.
Eskenazi, B., Warner, M., Sirtori, M., Fuerst, T., Rauch, S.A., Brambilla, P., Mocarelli, P.,
Rubinacci, A., 2014. Serum dioxin concentrations and bone density and struc-
ture in the Seveso Women's Health Study. Environ. Health Perspect. 122, 51e57.
Furue, M., Uenotsuchi, T., Urabe, K., Ishikawa, T., Kuwabara, M., 2005. Overview of
Yusho. J. Dermatol. Sci. 1, S3eS10.
Glynn, A.W., Michaelsson, K., Lind, P.M., Wolk, A., Aune, M., Atuma, S.,
Darnerud, P.O., Mallmin, H., 2000. Organochlorines and bone mineral density in
Swedish men from the general population. Osteoporos. Int. 11, 1036e1042.
Gray Jr., L.E., 1998. Xenoendocrine disrupters: laboratory studies on male repro-
ductive effects. Toxicol. Lett. 102e103, 331e335.
Greendale, G.A., Judd, H.L., 1993. The menopause: health implications and clinical
management. J. Am. Geriatr. Soc. 41, 426e436.
Guo, Y.L., Lin, C.J., Yao, W.J., Ryan, J.J., Hsu, C.C., 1994. Musculoskeletal changes in
children prenatally exposed to polychlorinated biphenyls and related com-
pounds (Yu-Cheng children). J. Toxicol. Environ. Health 41, 83e93.
Gutleb, A.C., Arvidsson, D., Orberg, J., Larsson, S., Skaare, J.U., Aleksandersen, M.,
Ropstad, E., Lind, P.M., 2010. Effects on bone tissue in ewes (Ovies aries) and
their foetuses exposed to PCB 118 and PCB 153. Toxicol. Lett. 192, 126e133.
Hangartner, T.N., 2007. A study of the long-term precision of dual-energy X-ray
absorptiometry bone densitometers and implications for the validity of the
least-signiﬁcant-change calculation. Osteoporos. Int. 18, 513e523.
Hans, D.B., Shepherd, J.A., Schwartz, E.N., Reid, D.M., Blake, G.M., Fordham, J.N.,
Fuerst, T., Hadji, P., Itabashi, A., Krieg, M.A., Lewiecki, E.M., 2008. Peripheral
dual-energy X-ray absorptiometry in the management of osteoporosis: the
2007 ISCD ofﬁcial positions. J. Clin. Densitom. 11, 188e206.
Hermsen, S.A., Larsson, S., Arima, A., Muneoka, A., Ihara, T., Sumida, H., Fukusato, T.,
Kubota, S., Yasuda, M., Lind, P.M., 2008. In utero and lactational exposure to
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) affects bone tissue in rhesus
monkeys. Toxicology 253, 147e152.
Hodgson, S., Thomas, L., Fattore, E., Lind, P.M., Alfven, T., Hellstrom, L.,
Hakansson, H., Carubelli, G., Fanelli, R., Jarup, L., 2008. Bone mineral density
changes in relation to environmental PCB exposure. Environ. Health Perspect.
116, 1162e1166.
Kim, M.J., Marchand, P., Henegar, C., Antignac, J.P., Alili, R., Poitou, C., Bouillot, J.L.,
Basdevant, A., Le Bizec, B., Barouki, R., Clement, K., 2011. Fate and complex
pathogenic effects of dioxins and polychlorinated biphenyls in obese subjects
before and after drastic weight loss. Environ. Health Perspect. 119, 377e383.
Korkalainen, M., Kallio, E., Olkku, A., Nelo, K., Ilvesaro, J., Tuukkanen, J., Mahonen, A.,
Viluksela, M., 2009. Dioxins interfere with differentiation of osteoblasts and
osteoclasts. Bone 44, 1134e1142.
Lind, P.M., Larsson, S., Oxlund, H., Hakansson, H., Nyberg, K., Eklund, T., Orberg, J.,
2000. Change of bone tissue composition and impaired bone strength in rats
J.-i. Fukushi et al. / Chemosphere 145 (2016) 25e33 33exposed to 3,3',4,4',5-pentachlorobiphenyl (PCB126). Toxicology 150, 41e51.
Lundberg, R., Lyche, J.L., Ropstad, E., Aleksandersen, M., Ronn, M., Skaare, J.U.,
Larsson, S., Orberg, J., Lind, P.M., 2006. Perinatal exposure to PCB 153, but not
PCB 126, alters bone tissue composition in female goat offspring. Toxicology
228, 33e40.
Miller, R.W., 1985. Congenital PCB poisoning: a reevaluation. Environ. Health Per-
spect. 60, 211e214.
Nishimura, N., Nishimura, H., Ito, T., Miyata, C., Izumi, K., Fujimaki, H.,
Matsumura, F., 2009. Dioxin-induced up-regulation of the active form of
vitamin D is the main cause for its inhibitory action on osteoblast activities,
leading to developmental bone toxicity. Toxicol. Appl. Pharmacol. 236,
301e309.
Pluim, H.J., de Vijlder, J.J., Olie, K., Kok, J.H., Vulsma, T., van Tijn, D.A., van der
Slikke, J.W., Koppe, J.G., 1993. Effects of pre- and postnatal exposure to chlori-
nated dioxins and furans on human neonatal thyroid hormone concentrations.
Environ. Health Perspect. 101, 504e508.
Rogan, W.J., Gladen, B.C., Hung, K.L., Koong, S.L., Shih, L.Y., Taylor, J.S., Wu, Y.C.,
Yang, D., Ragan, N.B., Hsu, C.C., 1988. Congenital poisoning by polychlorinated
biphenyls and their contaminants in Taiwan. Science 241, 334e336.
Sohoni, P., Sumpter, J.P., 1998. Several environmental oestrogens are also anti-an-
drogens. J. Endocrinol. 158, 327e339.
Sowers, M.R., Clark, M.K., Hollis, B., Wallace, R.B., Jannausch, M., 1992. Radial bone
mineral density in pre- and perimenopausal women: a prospective study of
rates and risk factors for loss. J. Bone Min. Res. 7, 647e657.
Todaka, T., Hirakawa, H., Hori, T., Tobiishi, K., Iida, T., Furue, M., 2007. Concentrations
of polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans, and non-ortho and mono-ortho polychlorinated biphenyls in blood of Yusho patients.
Chemosphere 66, 1983e1989.
Todaka, T., Hirakawa, H., Tobiihi, K., Iida, T., 2003. New protocol of dioxins analysis in
human blood. Fukuoka Igaku Zasshi 94, 148e157.
Todaka, T., Hori, T., Hirakawa, H., Kajiwara, J., Yasutake, D., Onozuka, D., Iida, T.,
Furue, M., 2009. Concentrations of polychlorinated biphenyls in blood of Yusho
patients over 35 years after the incident. Chemosphere 74, 902e909.
Tsukimori, K., Tokunaga, S., Shibata, S., Uchi, H., Nakayama, D., Ishimaru, T.,
Nakano, H., Wake, N., Yoshimura, T., Furue, M., 2008. Long-term effects of
polychlorinated biphenyls and dioxins on pregnancy outcomes in women
affected by the Yusho incident. Environ. Health Perspect. 116, 626e630.
Walkowiak, J., Wiener, J.A., Fastabend, A., Heinzow, B., Kramer, U., Schmidt, E.,
Steingruber, H.J., Wundram, S., Winneke, G., 2001. Environmental exposure to
polychlorinated biphenyls and quality of the home environment: effects on
psychodevelopment in early childhood. Lancet 358, 1602e1607.
Wallin, E., Rylander, L., Jonssson, B.A., Lundh, T., Isaksson, A., Hagmar, L., 2005.
Exposure to CB-153 and p,p'-DDE and bone mineral density and bone meta-
bolism markers in middle-aged and elderly men and women. Osteoporos. Int.
16, 2085e2094.
Weisglas-Kuperus, N., Patandin, S., Berbers, G.A., Sas, T.C., Mulder, P.G., Sauer, P.J.,
Hooijkaas, H., 2000. Immunologic effects of background exposure to poly-
chlorinated biphenyls and dioxins in Dutch preschool children. Environ. Health
Perspect. 108, 1203e1207.
Wolff, M.S., Deych, E., Ojo, F., Berkowitz, G.S., 2005. Predictors of organochlorines in
New York City pregnant women, 1998e2001. Environ. Res. 97, 170e177.
Yoshimura, T., 2012. Yusho: 43 years later. Kaohsiung J. Med. Sci. 28, S49eS52.
